Comparing Polymyxin B Delivered Directly into the Brain Alone Versus Combined with Intravenous Infusion for Treating Brain Infections Caused by Resistant Bacteria

What this Trial Is About

Researchers are comparing two ways of giving polymyxin B to treat severe brain infections caused by carbapenem-resistant Gram-negative bacteria CRGNB. The study looks at whether injecting the drug directly into the brain alone or combining this with an intravenous infusion works better to clear the infection and improve patient outcomes. It also measures the levels of polymyxin B in the cerebrospinal fluid CSF to understand how the drug acts in the body. Participants are divided into two groups. One group receives polymyxin B directly into the brain without an IV infusion. The other group receives polymyxin B both directly into the brain and through an IV infusion. All participants have an external ventricular drain to continuously drain CSF, and they must have been receiving polymyxin B treatment for at least five days before joining. During the study, researchers will monitor the 30-day mortality rate, bacterial clearance in the CSF at baseline, 1 week, 2 weeks, and 30 days after starting treatment, and the clinical cure rate at the end of treatment and 30 days afterward. Participants will be followed closely to assess how well the infection clears and to check safety. The study will continue until December 2026.

Intraventricular Administration of Intracranial Infections Caused by （Carbapenem-resistant Gram-negative Bacilli）CRGNB